Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal

Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.

Previous post Treasury yields slightly lower after subdued U.S. inflation reading in holiday-shortened session
Next post For savers, the end of 2023 is different: How new rules can help you sock away even more